The Activation of Protamine 1 Using Epigenome Editing Decreases the Proliferation of Tumorigenic Cells
DNA methyltransferases (DNMT) and histone deacetylases (HDAC) inhibitors are used as cancer epigenome drugs. However, these epigenetic drugs lack targeting specificity and could risk inducing genome instability and the expression of oncogenes. Therefore, there is a need to develop new therapeutic st...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Genome Editing |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgeed.2022.844904/full |